BackgroundContagious bovine pleuropneumonia (CBPP) caused by Mycoplasma mycoides subspecies mycoides (Mmm) is an important disease of cattle that causes serious economic losses. With the known effectiveness of new generation macrolides, tulathromycin and gamithromycin were assessed in comparison with oxytetracycline as a positive control and saline as a negative control for effectiveness in inhibiting lung lesion development, promoting resolution, preventing spread and bacteriological clearance in susceptible local cattle breeds in two separate studies in Kenya and Zambia. Animals were monitored for clinical signs, sero-conversion as well as detailed post-mortem examination for CBPP lesions.ResultsUsing the Hudson and Turner score for lesion type and size, tulathromycin protected 90%, gamithromycin 80%, and oxytetracycline 88% of treated animals in Kenya. In Zambia, all animals (100%) treated with macrolides were free of lung lesions, while oxytetracycline protected 77.5%. Using the mean adapted Hudson and Turner score, which includes clinical signs, post-mortem findings and serology, tulathromycin protected 82%, gamithromycin 56% and oxytetracycline 80% of the animals in Kenya whereas in Zambia, tulathromycin protected 98%, gamithromycin 94% and oxytetracycline 80%. The saline-treated groups had 93 and 92% lesions in Kenya and Zambia respectively, with Mmm recovered from 5/14 in Kenya and 10/13 animals in Zambia. Whereas the groups treated with macrolides were free from lesions in Zambia, in Kenya 5/15 tulathromycin-treated animals and 6/15 gamithromycin-treated animals showed lesions. Oxytetracycline-treated animals showed similarities with 3/14 and 4/15 showing lesions in Zambia and Kenya respectively and Mmm recovery from one animal in Kenya and six in Zambia. In both studies, lesion scores of saline-treated groups were significantly higher than those of the antibiotic treated groups (p < 0.001). In sentinel animals, CBPP lesions were detected and Mmm recovered from one and two animals mixed with the saline-treated groups in Kenya and Zambia respectively.ConclusionsThis study demonstrated that tulathromycin, a mycoplasmacidal, can achieve metaphylactic protection of up to 80%, while non-recovery of Mmm from sentinels suggests macrolides effectiveness in preventing spread of Mmm. It is recommended that further studies are conducted to evaluate strategies comparing vaccination alone or combining vaccination and antibiotics to control or eradicate CBPP.
Contagious bovine pleuropneumonia is an important disease of cattle. Many strategies employed for its eradication and control have had shortcomings. This study was conducted to determine the effects of long acting Oxytetracycline on its course. The study involved 30 indigenous zebu cattle sourced from an area free of the disease, infected by contact transmission and randomly allocated to Oxytetracycline or saline treatment groups. Clinical observations were recorded on the two groups concurrently. Cattle were tested for the disease using complement fixation test. The mean clinical scores of the groups for each observation was compared post treatment on GENSTAT using unpaired t-test for single sample in groups. Full post-mortem was conducted on the cattle and samples collected for Mmm SC isolation. The clinical scores were worse in the control treatment group; there was no fever in the Oxytetracycline-treated group post treatment. Lesions were observed in 93% of the control and 27% of the Oxytetracycline-treated group. In this study, as in others, Oxytetracycline was shown to lower the severity of the clinical signs of the disease. This is important at slaughter houses meat inspection where decision on whether to pass or condemn the animal is based on the clinical signs and post-mortem findings. Keywords: Contagious bovine Pleuropneumonia, Oxytetracycline, Bovine respiratory distress, Trans- boundary diseases
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.